G1 Therapeutics

G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company's product pipeline includes three clinical candidates: trilaciclib, a short-acting intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that preserves hematopoietic stem and progenitor cells and immune system function; lerociclib, an oral CDK4/6 inhibitor that inhibits tumor proliferation and growth; and G1T48, an oral selective estrogen receptor degrader that inhibits estrogen receptor driven tumor proliferation.
  • TickerGTHX
  • ISINUS3621LQ1099
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Wedbush Research

Wedbush Morning Call - Apr 01 2020 6:58AM

Wedbush Research

Wedbush Morning Call - Mar 29 2020 5:56PM

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Apr 01 2020 6:58AM

Wedbush Research

Wedbush Morning Call - Mar 29 2020 5:56PM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch